| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | BCRF1 |
| Uniprot No | P03180 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-170aa |
| 氨基酸序列 | TDQCDNFPQMLRDLRDAFSRVKTFFQTKDEVDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPEAKDHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTIKAR |
| 预测分子量 | 24.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCRF1重组蛋白的3篇参考文献示例(基于公开研究内容概括，非真实引用)：
---
1. **文献名称**：*Epstein-Barr Virus BCRF1 Protein Mimics Human IL-10 to Inhibit T Cell Responses*
**作者**：Moore, K.W., et al.
**摘要**：该研究发现EBV编码的BCRF1重组蛋白(vIL-10)与人类IL-10具有结构相似性，但免疫调节功能不同。通过体外实验证明，BCRF1可抑制T细胞增殖和IFN-γ分泌，帮助病毒逃避免疫监视。
2. **文献名称**：*Recombinant BCRF1 Enhances Viral Latency by Suppressing Antiviral Cytokine Production*
**作者**：Tsurumi, T., et al.
**摘要**：研究利用重组BCRF1蛋白处理免疫细胞，发现其通过下调STAT3信号通路抑制IL-12和TNF-α的产生，从而促进EBV在宿主细胞内的潜伏感染。
3. **文献名称**：*Functional Comparison of BCRF1 and Cellular IL-10 in Modulating Dendritic Cell Maturation*
**作者**：Hsu, D.H., et al.
**摘要**：通过对比重组BCRF1蛋白与人类IL-10的功能，发现BCRF1虽能抑制树突状细胞成熟，但其对MHC-II分子和共刺激因子的抑制作用更强，揭示了病毒免疫逃逸的分子机制。
---
如需具体文献，建议通过PubMed或Google Scholar搜索关键词：**BCRF1 recombinant protein**, **vIL-10 Epstein-Barr**, **EBV immune evasion**。
**Background of BCRF1 Recombinant Protein**
BCRF1. encoded by the Epstein-Barr virus (EBV), is a viral homolog of human interleukin-10 (hIL-10), often termed viral IL-10 (vIL-10). EBV, a gammaherpesvirus linked to malignancies and autoimmune disorders, employs BCRF1 to modulate host immune responses, promoting viral persistence and immune evasion. BCRF1 shares ~84% amino acid sequence identity with hIL-10 but exhibits distinct functional properties. While it retains immunosuppressive abilities—such as inhibiting cytokine synthesis in T cells and reducing antigen presentation—it lacks immunostimulatory effects of hIL-10. like B-cell proliferation or MHC class II upregulation.
Recombinant BCRF1 protein is produced via genetic engineering in heterologous expression systems (e.g., *E. coli*, mammalian cells). This allows large-scale production of purified protein for functional studies. Researchers use recombinant BCRF1 to dissect its immunomodulatory mechanisms, including interactions with the IL-10 receptor (IL-10R) and downstream signaling pathways like JAK-STAT. Such studies highlight its role in dampening antiviral immunity, facilitating EBV latency, and shaping tumor microenvironments in EBV-associated cancers.
Additionally, recombinant BCRF1 serves as a tool to explore therapeutic strategies. For instance, blocking BCRF1 activity may enhance antiviral or antitumor immunity, while its immunosuppressive properties could be harnessed to treat inflammatory diseases. Structural analyses of recombinant BCRF1 further aid in designing targeted inhibitors or engineered cytokines. Overall, BCRF1 recombinant protein is pivotal for understanding viral pathogenesis and developing interventions against EBV-related diseases.
×
